Data on drug overdose death rates, by drug type and selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. SOURCE: NCHS, National Vital Statistics System, numerator data from annual public-use Mortality Files; denominator data from U.S. Census Bureau national population estimates; and Murphy SL, Xu JQ, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final data for 2018. National Vital Statistics Reports; vol 69 no 13. Hyattsville, MD: National Center for Health Statistics.2021. Available from: https://www.cdc.gov/nchs/products/nvsr.htm. For more information on the National Vital Statistics System, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

A. SUMMARY This dataset includes unintentional drug overdose death rates by race/ethnicity by year. This dataset is created using data from the California Electronic Death Registration System (CA-EDRS) via the Vital Records Business Intelligence System (VRBIS). Substance-related deaths are identified by reviewing the cause of death. Deaths caused by opioids, methamphetamine, and cocaine are included. Homicides and suicides are excluded. Ethnic and racial groups with fewer than 10 events are not tallied separately for privacy reasons but are included in the “all races” total.

Unintentional drug overdose death rates are calculated by dividing the total number of overdose deaths by race/ethnicity by the total population size for that demographic group and year and then multiplying by 100,000. The total population size is based on estimates from the US Census Bureau County Population Characteristics for San Francisco, 2022 Vintage by age, sex, race, and Hispanic origin.

These data differ from the data shared in the Preliminary Unintentional Drug Overdose Death by Year dataset since this dataset uses finalized counts of overdose deaths associated with cocaine, methamphetamine, and opioids only.

B. HOW THE DATASET IS CREATED This dataset is created by copying data from the Annual Substance Use Trends in San Francisco report from the San Francisco Department of Public Health Center on Substance Use and Health.

C. UPDATE PROCESS This dataset will be updated annually, typically at the end of the year.

D. HOW TO USE THIS DATASET N/A

E. RELATED DATASETS Overdose-Related 911 Responses by Emergency Medical Services Preliminary Unintentional Drug Overdose Deaths San Francisco Department of Public Health Substance Use Services

F. CHANGE LOG

• 12/16/2024 - Updated with 2023 data. Asian/Pacific Islander race/ethnicity group was changed to Asian.
• 12/16/2024 - Past year totals by race/ethnicity were revised after obtaining accurate race/ethnicity for some decedents that were previously marked as “unknown” race/ethnicity.

This data contains provisional counts for drug overdose deaths based on a current flow of mortality data in the National Vital Statistics System. Counts for the most recent final annual data are provided for comparison. National provisional counts include deaths occurring within the 50 states and the District of Columbia as of the date specified and may not include all deaths that occurred during a given time period. Provisional counts are often incomplete and causes of death may be pending investigation (see Technical notes) resulting in an underestimate relative to final counts. To address this, methods were developed to adjust provisional counts for reporting delays by generating a set of predicted provisional counts (see Technical notes). Starting in June 2018, this monthly data release will include both reported and predicted provisional counts.

The provisional data include: (a) the reported and predicted provisional counts of deaths due to drug overdose occurring nationally and in each jurisdiction; (b) the percentage changes in provisional drug overdose deaths for the current 12 month-ending period compared with the 12-month period ending in the same month of the previous year, by jurisdiction; and (c) the reported and predicted provisional counts of drug overdose deaths involving specific drugs or drug classes occurring nationally and in selected jurisdictions. The reported and predicted provisional counts represent the numbers of deaths due to drug overdose occurring in the 12-month periods ending in the month indicated. These counts include all seasons of the year and are insensitive to variations by seasonality. Deaths are reported by the jurisdiction in which the death occurred.

Several data quality metrics, including the percent completeness in overall death reporting, percentage of deaths with cause of death pending further investigation, and the percentage of drug overdose deaths with specific drugs or drug classes reported are included to aid in interpretation of provisional data as these measures are related to the accuracy of provisional counts (see Technical notes). Reporting of the specific drugs and drug classes involved in drug overdose deaths varies by jurisdiction, and comparisons of death rates involving specific drugs across selected jurisdictions should not be made (see Technical notes). Provisional data will be updated on a monthly basis as additional records are received.

Technical notes

Nature and sources of data

Provisional drug overdose death counts are based on death records received and processed by the National Center for Health Statistics (NCHS) as of a specified cutoff date. The cutoff date is generally the first Sunday of each month. National provisional estimates include deaths occurring within the 50 states and the District of Columbia. NCHS receives the death records from state vital registration offices through the Vital Statistics Cooperative Program (VSCP).

The timeliness of provisional mortality surveillance data in the National Vital Statistics System (NVSS) database varies by cause of death. The lag time (i.e., the time between when the death occurred and when the data are available for analysis) is longer for drug overdose deaths compared with other causes of death (1). Thus, provisional estimates of drug overdose deaths are reported 6 months after the date of death.

Provisional death counts presented in this data visualization are for “12-month ending periods,” defined as the number of deaths occurring in the 12-month period ending in the month indicated. For example, the 12-month ending period in June 2017 would include deaths occurring from July 1, 2016, through June 30, 2017. The 12-month ending period counts include all seasons of the year and are insensitive to reporting variations by seasonality. Counts for the 12-month period ending in the same month of the previous year are shown for comparison. These provisional counts of drug overdose deaths and related data quality metrics are provided for public health surveillance and monitoring of emerging trends. Provisional drug overdose death data are often incomplete, and the degree of completeness varies by jurisdiction and 12-month ending period. Consequently, the numbers of drug overdose deaths are underestimated based on provisional data relative to final data and are subject to random variation. Methods to adjust provisional counts have been developed to provide predicted provisional counts of drug overdose deaths, accounting for delayed reporting (see Percentage of records pending investigation and Adjustments for delayed reporting).

Provisional data are based on available records that meet certain data quality criteria at the time of analysis and may not include all deaths that occurred during a given time period. Therefore, they should not be considered comparable with final data and are subject to change.

Cause-of-death classification and definition of drug deaths
Mortality statistics are compiled in accordance with World Health Organization (WHO) regulations specifying that WHO member nations classify and code causes of death with the current revision of the International Statistical Classification of Diseases and Related Health Problems (ICD). ICD provides the basic guidance used in virtually all countries to code and classify causes of death. It provides not only disease, injury, and poisoning categories but also the rules used to select the single underlying cause of death for tabulation from the several diagnoses that may be reported on a single death certificate, as well as definitions, tabulation lists, the format of the death certificate, and regulations on use of the classification. Causes of death for data presented in this report were coded according to ICD guidelines described in annual issues of Part 2a of the NCHS Instruction Manual (2).

Drug overdose deaths are identified using underlying cause-of-death codes from the Tenth Revision of ICD (ICD–10): X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), and Y10–Y14 (undetermined). Drug overdose deaths involving selected drug categories are identified by specific multiple cause-of-death codes. Drug categories presented include: heroin (T40.1); natural opioid analgesics, including morphine and codeine, and semisynthetic opioids, including drugs such as oxycodone, hydrocodone, hydromorphone, and oxymorphone (T40.2); methadone, a synthetic opioid (T40.3); synthetic opioid analgesics other than methadone, including drugs such as fentanyl and tramadol (T40.4); cocaine (T40.5); and psychostimulants with abuse potential, which includes methamphetamine (T43.6). Opioid overdose deaths are identified by the presence of any of the following MCOD codes: opium (T40.0); heroin (T40.1); natural opioid analgesics (T40.2); methadone (T40.3); synthetic opioid analgesics other than methadone (T40.4); or other and unspecified narcotics (T40.6). This latter category includes drug overdose deaths where ‘opioid’ is reported without more specific information to assign a more specific ICD–10 code (T40.0–T40.4) (3,4). Among deaths with an underlying cause of drug overdose, the percentage with at least one drug or drug class specified is defined as that with at least one ICD–10 multiple cause-of-death code in the range T36–T50.8.

Drug overdose deaths may involve multiple drugs; therefore, a single death might be included in more than one category when describing the number of drug overdose deaths involving specific drugs. For example, a death that involved both heroin and fentanyl would be included in both the number of drug overdose deaths involving heroin and the number of drug overdose deaths involving synthetic opioids other than methadone.

Selection of specific states and other jurisdictions to report
Provisional counts are presented by the jurisdiction in which the death occurred (i.e., the reporting jurisdiction). Data quality and timeliness for drug overdose deaths vary by reporting jurisdiction. Provisional counts are presented for reporting jurisdictions based on measures of data quality: the percentage of records where the manner of death is listed as “pending investigation,” the overall completeness of the data, and the percentage of drug overdose death records with specific drugs or drug classes recorded. These criteria are defined below.

Percentage of records pending investigation

Drug overdose deaths often require lengthy investigations, and death certificates may be initially filed with a manner of death “pending investigation” and/or with a preliminary or unknown cause of death. When the percentage of records reported as “pending investigation” is high for a given jurisdiction, the number of drug overdose deaths is likely to be underestimated. For jurisdictions reporting fewer than 1% of records as “pending investigation”, the provisional number of drug overdose deaths occurring in the fourth quarter of 2015 was approximately 5% lower than the final count of drug overdose deaths occurring in that same time period. For jurisdictions reporting greater than 1% of records as “pending investigation” the provisional counts of drug overdose deaths may underestimate the final count of drug overdose deaths by as much as 30%. Thus, jurisdictions are included in Table 2 if 1% or fewer of their records in NVSS are reported as “pending investigation,” following a 6-month lag for the 12-month ending periods included in the dashboard. Values for records pending investigation are updated with each monthly release and reflect the most current data available.

Percent completeness

NCHS receives monthly counts of the estimated number of deaths from each jurisdictional vital registration offices (referred to as “control counts”). This number represents the best estimate of how many

This dataset describes drug poisoning deaths at the U.S. and state level by selected demographic characteristics, and includes age-adjusted death rates for drug poisoning. Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug-poisoning deaths are defined as having ICD–10 underlying cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), or Y10–Y14 (undetermined intent). Estimates are based on the National Vital Statistics System multiple cause-of-death mortality files (1). Age-adjusted death rates (deaths per 100,000 U.S. standard population for 2000) are calculated using the direct method. Populations used for computing death rates for 2011–2017 are postcensal estimates based on the 2010 U.S. census. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for noncensus years before 2010 are revised using updated intercensal population estimates and may differ from rates previously published. Death rates for some states and years may be low due to a high number of unresolved pending cases or misclassification of ICD–10 codes for unintentional poisoning as R99, “Other ill-defined and unspecified causes of mortality” (2). For example, this issue is known to affect New Jersey in 2009 and West Virginia in 2005 and 2009 but also may affect other years and other states. Drug poisoning death rates may be underestimated in those instances. REFERENCES 1. National Center for Health Statistics. National Vital Statistics System: Mortality data. Available from: http://www.cdc.gov/nchs/deaths.htm. CDC. CDC Wonder: Underlying cause of death 1999–2016. Available from: http://wonder.cdc.gov/wonder/help/ucd.html.

This dataset contains counts of deaths for California as a whole based on information entered on death certificates. Final counts are derived from static data and include out-of-state deaths to California residents, whereas provisional counts are derived from incomplete and dynamic data. Provisional counts are based on the records available when the data was retrieved and may not represent all deaths that occurred during the time period. Deaths involving injuries from external or environmental forces, such as accidents, homicide and suicide, often require additional investigation that tends to delay certification of the cause and manner of death. This can result in significant under-reporting of these deaths in provisional data.

The final data tables include both deaths that occurred in California regardless of the place of residence (by occurrence) and deaths to California residents (by residence), whereas the provisional data table only includes deaths that occurred in California regardless of the place of residence (by occurrence). The data are reported as totals, as well as stratified by age, gender, race-ethnicity, and death place type. Deaths due to all causes (ALL) and selected underlying cause of death categories are provided. See temporal coverage for more information on which combinations are available for which years.

The cause of death categories are based solely on the underlying cause of death as coded by the International Classification of Diseases. The underlying cause of death is defined by the World Health Organization (WHO) as "the disease or injury which initiated the train of events leading directly to death, or the circumstances of the accident or violence which produced the fatal injury." It is a single value assigned to each death based on the details as entered on the death certificate. When more than one cause is listed, the order in which they are listed can affect which cause is coded as the underlying cause. This means that similar events could be coded with different underlying causes of death depending on variations in how they were entered. Consequently, while underlying cause of death provides a convenient comparison between cause of death categories, it may not capture the full impact of each cause of death as it does not always take into account all conditions contributing to the death.

U.S. Opiate Prescriptions

Accidental death by fatal drug overdose is a rising trend in the United States. What can you do to help?

This dataset contains summaries of prescription records for 250 common opioid and non-opioid drugs written by 25,000 unique licensed medical professionals in 2014 in the United States for citizens covered under Class D Medicare as well as some metadata about the doctors themselves. This is a small subset of data that was sourced from cms.gov. The full dataset contains almost 24 million prescription instances in long format. I have cleaned and compiled this data here in a format with 1 row per prescriber and limited the approximately 1 million total unique prescribers down to 25,000 to keep it manageable. If you are interested in more data, you can get the script I used to assemble the dataset here and run it yourself. The main data is in prescriber-info.csv. There is also opioids.csv that contains the names of all opioid drugs included in the data and overdoses.csv that contains information on opioid related drug overdose fatalities.

The increase in overdose fatalities is a well-known problem, and the search for possible solutions is an ongoing effort. My primary interest in this dataset is detecting sources of significant quantities of opiate prescriptions. However, there is plenty of other studies to perform, and I am interested to see what other Kagglers will come up with, or if they can improve the model I have already built.

The data consists of the following characteristics for each prescriber

• NPI – unique National Provider Identifier number
• Gender - (M/F)
• State - U.S. State by abbreviation
• Credentials - set of initials indicative of medical degree
• Specialty - description of type of medicinal practice
• A long list of drugs with numeric values indicating the total number of prescriptions written for the year by that individual
• Opioid.Prescriber - a boolean label indicating whether or not that individual prescribed opiate drugs more than 10 times in the year

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

Accuracy:Data are from the "Suspect drug-related and confirmed opioid toxicity deaths in Ottawa Public Health" custom report provided by the OCCO.Confirmed opioid toxicity deaths are deaths for which a coroner or forensic pathologist determined the cause of death to be drug toxicity with opioid involvement. These may include drug toxicity deaths involving multiple substances. Conclusions on cause of death may take several months to become available.Deaths have been assigned to public health unit based on six-digit postal code of the residence of the decedent. If residence postal code was unavailable, the postal code of the incident location was used. If postal code of the incident location was unavailable, the postal code of the death location was used. This methodology aligns with how deaths are assigned in PHO's Interactive Opioid Tool.The attribution of deaths to an ONS neighbourhood reflects the location of incident or death, based on postal code, and not necessarily the neighbourhood where the decedent resided. Postal codes that straddle more than one ONS neighbourhood are allocated to neighbourhoods based on the area of overlap between the straddled neighbourhoods. If there is no postal code information for the location of incident, the location of incident/death is not attributed to an ONS neighbourhood. Update Frequency: Yearly

Attributes:ONS neighbourhood ID – the identification number for the Ottawa Neighbourhood Study (ONS) neighbourhood.ONS neighbourhood name – the name of the ONS neighbourhood.Cumulative number of confirmed opioid toxicity deaths – the cumulative number of confirmed opioid toxicity deaths of Ottawa residents based on the location of the incident.Yearly average of confirmed opioid toxicity deaths – the cumulative number of confirmed opioid toxicity deaths of Ottawa residents divided by the number of years of data.Average yearly rate (per 100,000 population) of confirmed opioid toxicity deaths – the average of the yearly rate (per 100,000 population) of confirmed opioid toxicity deaths of Ottawa residents. To calculate each neighbourhood’s annual rate, the total number of drug overdose deaths by ONS neighbourhood is divided by the neighbourhood population estimate for that year and then multiplied by 100,000. This gives us an annual neighbourhood rate per 100,000 population for each year of data and neighbourhood. For each neighbourhood, the annual rates are summed to create a cumulative neighbourhood rate, which is then divided by the number of years to create the average yearly rate for each neighbourhood.Years – the range of years during which the deaths occurred. Contact: Ottawa Public Health Epidemiology Team

Number and percentage of deaths, by month and place of residence, 1991 to most recent year.

County Cancer Death Rates

County-level cancer death rates with related variables

By Noah Rippner [source]

About this dataset

This dataset provides comprehensive information on county-level cancer death and incidence rates, as well as various related variables. It includes data on age-adjusted death rates, average deaths per year, recent trends in cancer death rates, recent 5-year trends in death rates, and average annual counts of cancer deaths or incidence. The dataset also includes the federal information processing standards (FIPS) codes for each county.

Additionally, the dataset indicates whether each county met the objective of a targeted death rate of 45.5. The recent trend in cancer deaths or incidence is also captured for analysis purposes.

The purpose of the death.csv file within this dataset is to offer detailed information specifically concerning county-level cancer death rates and related variables. On the other hand, the incd.csv file contains data on county-level cancer incidence rates and additional relevant variables.

To provide more context and understanding about the included data points, there is a separate file named cancer_data_notes.csv. This file serves to provide informative notes and explanations regarding the various aspects of the cancer data used in this dataset.

Please note that this particular description provides an overview for a linear regression walkthrough using this dataset based on Python programming language. It highlights how to source and import the data properly before moving into data preparation steps such as exploratory analysis. The walkthrough further covers model selection and important model diagnostics measures.

It's essential to bear in mind that this example serves as an initial attempt at creating a multivariate Ordinary Least Squares regression model using these datasets from various sources like cancer.gov along with US Census American Community Survey data. This baseline model allows easy comparisons with future iterations intended for improvements or refinements.

Important columns found within this extensively documented Kaggle dataset include County names along with their corresponding FIPS codes—a standardized coding system by Federal Information Processing Standards (FIPS). Moreover,Met Objective of 45.5? (1) column denotes whether a specific county achieved the targeted objective of a death rate of 45.5 or not.

Overall, this dataset aims to offer valuable insights into county-level cancer death and incidence rates across various regions, providing policymakers, researchers, and healthcare professionals with essential information for analysis and decision-making purposes

How to use the dataset

• Familiarize Yourself with the Columns:

  • County: The name of the county.
  • FIPS: The Federal Information Processing Standards code for the county.
  • Met Objective of 45.5? (1): Indicates whether the county met the objective of a death rate of 45.5 (Boolean).
  • Age-Adjusted Death Rate: The age-adjusted death rate for cancer in the county.
  • Average Deaths per Year: The average number of deaths per year due to cancer in the county.
  • Recent Trend (2): The recent trend in cancer death rates/incidence in the county.
  • Recent 5-Year Trend (2) in Death Rates: The recent 5-year trend in cancer death rates/incidence in the county.
  • Average Annual Count: The average annual count of cancer deaths/incidence in the county.

• Determine Counties Meeting Objective: Use this dataset to identify counties that have met or not met an objective death rate threshold of 45.5%. Look for entries where Met Objective of 45.5? (1) is marked as True or False.

• Analyze Age-Adjusted Death Rates: Study and compare age-adjusted death rates across different counties using Age-Adjusted Death Rate values provided as floats.

• Explore Average Deaths per Year: Examine and compare average annual counts and trends regarding deaths caused by cancer, using Average Deaths per Year as a reference point.

• Investigate Recent Trends: Assess recent trends related to cancer deaths or incidence by analyzing data under columns such as Recent Trend, Recent Trend (2), and Recent 5-Year Trend (2) in Death Rates. These columns provide information on how cancer death rates/incidence have changed over time.

• Compare Counties: Utilize this dataset to compare counties based on their cancer death rates and related variables. Identify counties with lower or higher average annual counts, age-adjusted death rates, or recent trends to analyze and understand the factors contributing ...

BackgroundDrug overdose causes approximately 183,000 deaths worldwide annually and 50,000 deaths in Canada and the United States combined. Drug-related deaths are concentrated among young people, leading to a substantial burden of disease and loss of potential life years. Understanding the epidemiology, patterns of care, and prognosis of drug-related prehospital emergencies may lead to improved outcomes.MethodsWe conducted a retrospective cohort study of out-of-hospital cardiac arrests with drug-related and presumed cardiac causes between 2007 and 2013 using the Toronto Regional RescuNet Epistry database. The primary outcome was survival to hospital discharge. We computed standardized case fatality rates, and odds ratios of survival to hospital discharge for cardiac arrests with drug-related versus presumed cardiac causes, adjusting for confounders using logistic regression.ResultsThe analysis involved 21,497 cardiac arrests, including 378 (1.8%) drug-related and 21,119 (98.2%) presumed cardiac. Compared with the presumed cardiac group, drug-related arrest patients were younger and less likely to receive bystander resuscitation, have initial shockable cardiac rhythms, or be transported to hospital. There were no significant differences in emergency medical service response times, return of spontaneous circulation, or survival to discharge. Standardized case fatality rates confirmed that these effects were not due to age or sex differences. Adjusting for known predictors of survival, drug-related cardiac arrest was associated with increased odds of survival to hospital discharge (OR1.44, 95%CI 1.15–1.81).InterpretationIn out-of-hospital cardiac arrest, patients with drug-related causes are less likely than those with presumed cardiac causes to receive bystander resuscitation or have an initial shockable rhythm, but are more likely to survive after accounting for predictors of survival. The demographics and outcomes among drug-related cardiac arrest patients offers unique opportunities for prehospital intervention.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

Cancer Mortality & Incidence Rates: (Country LVL)

Investigating Cancer Trends over time

By Data Exercises [source]

About this dataset

This dataset is a comprehensive collection of data from county-level cancer mortality and incidence rates in the United States between 2000-2014. This data provides an unprecedented level of detail into cancer cases, deaths, and trends at a local level. The included columns include County, FIPS, age-adjusted death rate, average death rate per year, recent trend (2) in death rates, recent 5-year trend (2) in death rates and average annual count for each county. This dataset can be used to provide deep insight into the patterns and effects of cancer on communities as well as help inform policy decisions related to mitigating risk factors or increasing preventive measures such as screenings. With this comprehensive set of records from across the United States over 15 years, you will be able to make informed decisions regarding individual patient care or policy development within your own community!

More Datasets

For more datasets, click here.

Featured Notebooks

• 🚨 Your notebook can be here! 🚨!

How to use the dataset

This dataset provides comprehensive US county-level cancer mortality and incidence rates from 2000 to 2014. It includes the mortality and incidence rate for each county, as well as whether the county met the objective of 45.5 deaths per 100,000 people. It also provides information on recent trends in death rates and average annual counts of cases over the five year period studied.

This dataset can be extremely useful to researchers looking to study trends in cancer death rates across counties. By using this data, researchers will be able to gain valuable insight into how different counties are performing in terms of providing treatment and prevention services for cancer patients and whether preventative measures and healthcare access are having an effect on reducing cancer mortality rates over time. This data can also be used to inform policy makers about counties needing more target prevention efforts or additional resources for providing better healthcare access within at risk communities.

When using this dataset, it is important to pay close attention to any qualitative columns such as “Recent Trend” or “Recent 5-Year Trend (2)” that may provide insights into long term changes that may not be readily apparent when using quantitative variables such as age-adjusted death rate or average deaths per year over shorter periods of time like one year or five years respectively. Additionally, when studying differences between different counties it is important to take note of any standard FIPS code differences that may indicate that data was collected by a different source with a difference methodology than what was used in other areas studied

Research Ideas

• Using this dataset, we can identify patterns in cancer mortality and incidence rates that are statistically significant to create treatment regimens or preventive measures specifically targeting those areas.
• This data can be useful for policymakers to target areas with elevated cancer mortality and incidence rates so they can allocate financial resources to these areas more efficiently.
• This dataset can be used to investigate which factors (such as pollution levels, access to medical care, genetic make up) may have an influence on the cancer mortality and incidence rates in different US counties

Acknowledgements

If you use this dataset in your research, please credit the original authors. Data Source

License

License: Dataset copyright by authors - You are free to: - Share - copy and redistribute the material in any medium or format for any purpose, even commercially. - Adapt - remix, transform, and build upon the material for any purpose, even commercially. - You must: - Give appropriate credit - Provide a link to the license, and indicate if changes were made. - ShareAlike - You must distribute your contributions under the same license as the original. - Keep intact - all notices that refer to this license, including copyright notices.

Columns

File: death .csv | Column name | Description | |:-------------------------------------------|:-------------------------------------------------------------------...

THIS DATASET WAS LAST UPDATED AT 8:11 PM EASTERN ON AUG. 30

OVERVIEW

2019 had the most mass killings since at least the 1970s, according to the Associated Press/USA TODAY/Northeastern University Mass Killings Database.

In all, there were 45 mass killings, defined as when four or more people are killed excluding the perpetrator. Of those, 33 were mass shootings . This summer was especially violent, with three high-profile public mass shootings occurring in the span of just four weeks, leaving 38 killed and 66 injured.

A total of 229 people died in mass killings in 2019.

The AP's analysis found that more than 50% of the incidents were family annihilations, which is similar to prior years. Although they are far less common, the 9 public mass shootings during the year were the most deadly type of mass murder, resulting in 73 people's deaths, not including the assailants.

One-third of the offenders died at the scene of the killing or soon after, half from suicides.

About this Dataset

The Associated Press/USA TODAY/Northeastern University Mass Killings database tracks all U.S. homicides since 2006 involving four or more people killed (not including the offender) over a short period of time (24 hours) regardless of weapon, location, victim-offender relationship or motive. The database includes information on these and other characteristics concerning the incidents, offenders, and victims.

The AP/USA TODAY/Northeastern database represents the most complete tracking of mass murders by the above definition currently available. Other efforts, such as the Gun Violence Archive or Everytown for Gun Safety may include events that do not meet our criteria, but a review of these sites and others indicates that this database contains every event that matches the definition, including some not tracked by other organizations.

This data will be updated periodically and can be used as an ongoing resource to help cover these events.

Using this Dataset

To get basic counts of incidents of mass killings and mass shootings by year nationwide, use these queries:

Mass killings by year

Mass shootings by year

To get these counts just for your state:

Filter killings by state

Definition of "mass murder"

Mass murder is defined as the intentional killing of four or more victims by any means within a 24-hour period, excluding the deaths of unborn children and the offender(s). The standard of four or more dead was initially set by the FBI.

This definition does not exclude cases based on method (e.g., shootings only), type or motivation (e.g., public only), victim-offender relationship (e.g., strangers only), or number of locations (e.g., one). The time frame of 24 hours was chosen to eliminate conflation with spree killers, who kill multiple victims in quick succession in different locations or incidents, and to satisfy the traditional requirement of occurring in a “single incident.”

Offenders who commit mass murder during a spree (before or after committing additional homicides) are included in the database, and all victims within seven days of the mass murder are included in the victim count. Negligent homicides related to driving under the influence or accidental fires are excluded due to the lack of offender intent. Only incidents occurring within the 50 states and Washington D.C. are considered.

Methodology

Project researchers first identified potential incidents using the Federal Bureau of Investigation’s Supplementary Homicide Reports (SHR). Homicide incidents in the SHR were flagged as potential mass murder cases if four or more victims were reported on the same record, and the type of death was murder or non-negligent manslaughter.

Cases were subsequently verified utilizing media accounts, court documents, academic journal articles, books, and local law enforcement records obtained through Freedom of Information Act (FOIA) requests. Each data point was corroborated by multiple sources, which were compiled into a single document to assess the quality of information.

In case(s) of contradiction among sources, official law enforcement or court records were used, when available, followed by the most recent media or academic source.

Case information was subsequently compared with every other known mass murder database to ensure reliability and validity. Incidents listed in the SHR that could not be independently verified were excluded from the database.

Project researchers also conducted extensive searches for incidents not reported in the SHR during the time period, utilizing internet search engines, Lexis-Nexis, and Newspapers.com. Search terms include: [number] dead, [number] killed, [number] slain, [number] murdered, [number] homicide, mass murder, mass shooting, massacre, rampage, family killing, familicide, and arson murder. Offender, victim, and location names were also directly searched when available.

This project started at USA TODAY in 2012.

Contacts

Contact AP Data Editor Justin Myers with questions, suggestions or comments about this dataset at jmyers@ap.org. The Northeastern University researcher working with AP and USA TODAY is Professor James Alan Fox, who can be reached at j.fox@northeastern.edu or 617-416-4400.

NOTE: This dataset has been retired and marked as historical-only.

Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age.

Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine.

Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS).

Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death.

Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test.

CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset.

Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000.

Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people.

Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population.

Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019.

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week.

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.

For all datasets related to COVID-19, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=covid-19.

Data Source: Illinois' National Electronic Disease Surveillance System (I-NEDSS), Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE), U.S. Census Bureau American Community Survey

The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since the first reported coronavirus case in Washington State on Jan. 21, 2020, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 31 jurisdictions; 30 jurisdictions also reported data on deaths among people who received one or more additional or booster dose; 28 jurisdictions reported cases among people who received two or more additional or booster doses; and 26 jurisdictions reported deaths among people who received two or more additional or booster doses. This list will be updated as more jurisdictions participate. Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6 months through 1 year, half of the single-year population counts for ages 0 through 1 year were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred. For the primary series analysis, age-standardized rates include ages 12 years and older from April 4, 2021 through December 4, 2021, ages 5 years and older from December 5, 2021 through July 30, 2022 and ages 6 months and older from July 31, 2022 onwards. For the booster dose analysis, age-standardized rates include ages 18 years and older from September 19, 2021 through December 25, 2021, ages 12 years and older from December 26, 2021, and ages 5 years and older from June 5, 2022 onwards. Small numbers could contribute to less precision when calculating death rates among some groups. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage. Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated with a primary series either overall or with a booster dose. Publications: Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138

This is a source dataset for a Let's Get Healthy California indicator at https://letsgethealthy.ca.gov/. Infant Mortality is defined as the number of deaths in infants under one year of age per 1,000 live births. Infant mortality is often used as an indicator to measure the health and well-being of a community, because factors affecting the health of entire populations can also impact the mortality rate of infants. Although California’s infant mortality rate is better than the national average, there are significant disparities, with African American babies dying at more than twice the rate of other groups. Data are from the Birth Cohort Files. The infant mortality indicator computed from the birth cohort file comprises birth certificate information on all births that occur in a calendar year (denominator) plus death certificate information linked to the birth certificate for those infants who were born in that year but subsequently died within 12 months of birth (numerator). Studies of infant mortality that are based on information from death certificates alone have been found to underestimate infant death rates for infants of all race/ethnic groups and especially for certain race/ethnic groups, due to problems such as confusion about event registration requirements, incomplete data, and transfers of newborns from one facility to another for medical care. Note there is a separate data table "Infant Mortality by Race/Ethnicity" which is based on death records only, which is more timely but less accurate than the Birth Cohort File. Single year shown to provide state-level data and county totals for the most recent year. Numerator: Infants deaths (under age 1 year). Denominator: Live births occurring to California state residents. Multiple years aggregated to allow for stratification at the county level. For this indicator, race/ethnicity is based on the birth certificate information, which records the race/ethnicity of the mother. The mother can “decline to state”; this is considered to be a valid response. These responses are not displayed on the indicator visualization.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes

Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

Dataset and data visualization details:

These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.

Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be updated as more jurisdictions participate.

Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with at least a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6-12 months, half of the single-year population counts for ages <12 months were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred.

Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage.

Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated without an updated (bivalent) booster dose) or vaccinated with an updated (bivalent) booster dose.

Archive: An archive of historic data, including April 3, 2021-September 24, 2022 and posted on October 21, 2022 is available on data.cdc.gov. The analysis by vaccination status (unvaccinated and at least a primary series) for 31 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/3rge-nu2a. The analysis for one booster dose (unvaccinated, primary series only, and at least one booster dose) in 31 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/d6p8-wqjm. The analysis for two booster doses (unvaccinated, primary series only, one booster dose, and at least two booster doses) in 28 jurisdictions is posted here: https://data.cdc.gov/Public-Health-Surveillance/Rates-of-COVID-19-Cases-or-Deaths-by-Age-Group-and/ukww-au2k.

References

Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290.

Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138

Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152

The opioid epidemic is an ongoing public health crisis. In North Carolina, overdose deaths due to illicit opioid overdose have sharply increased over the last 5–7 years. Buprenorphine is a U.S. Food and Drug Administration approved medication for treatment of opioid use disorder and is obtained by prescription. Prior to January 2023, providers had to obtain a waiver and were limited in the number of patients that they could prescribe buprenorphine. Thus, identifying counties where increasing buprenorphine would yield the greatest overall reduction in overdose death can help policymakers target certain geographical regions to inform an effective public health response. We propose a Bayesian spatio-temporal model that relates yearly, county-level changes in illicit opioid overdose death rates to changes in buprenorphine prescriptions. We use our model to forecast the statewide count and rate of illicit opioid overdose deaths in future years, and we use nonlinear constrained optimization to identify the optimal buprenorphine increase in each county under a set of constraints on available resources. Our model estimates a negative relationship between death rate and increasing buprenorphine after accounting for other covariates, and our identified optimal single-year allocation strategy is estimated to reduce opioid overdose deaths by over 5%. Supplementary materials for this article are available online.